Ardent Health Partners, Inc. (ARDT)
NYSE:ARDT
Want to see ARDT full AI Analyst Report?
Top Page
Ardent Health Partners, Inc.
(NYSE:ARDT)
Select Model
Select Model
Rating:67Neutral
Price Target:
$11.00
▲(11.00% Upside)
Action:ReiteratedDate:05/06/26
ARDT scores as moderately attractive, driven primarily by improved financial footing (meaningful deleveraging and stronger free cash flow) and a favorable valuation (low P/E). The score is tempered by a mixed operating picture (2025 margin and earnings softness) and only moderately supportive technicals (below the 200-day moving average), while the latest earnings call was net positive but included notable payer-mix and cost headwinds with guidance maintained rather than raised.
Positive Factors
Deleveraged balance sheet
Material deleveraging to ~0.7x debt-to-equity and improved equity reduces financial risk and interest burden, increasing capacity to fund growth or absorb downturns. This enhances strategic optionality, supports capital allocation and makes the business more resilient to cyclical volume shocks.
Negative Factors
Profitability compression in 2025
A meaningful decline in margins and slipping top-line in 2025 signals structural operating or mix pressures that reduce retained earnings and ROE. Persistently lower profitability constrains reinvestment, limits cushion against reimbursement shifts, and reduces the payoff from deleveraging over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraged balance sheet
Material deleveraging to ~0.7x debt-to-equity and improved equity reduces financial risk and interest burden, increasing capacity to fund growth or absorb downturns. This enhances strategic optionality, supports capital allocation and makes the business more resilient to cyclical volume shocks.
Read all positive factors
Ardent Health Partners, Inc. (ARDT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.34B
Dividend YieldN/A
Average Volume (3M)407.60K
Price to Earnings (P/E)7.6
Beta (1Y)0.59
Revenue Growth6.72%
EPS Growth-39.63%
CountryUS
Employees19,200
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.97
Shares Outstanding143,095,660
10 Day Avg. Volume333,763
30 Day Avg. Volume407,603
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.74
Price to Sales (P/S)0.20
P/FCF Ratio4.81
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.33
Enterprise Value/Ebitda4.02
Forecast
1Y Price Target
$12.70Price Target Upside28.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.12
Revenue Forecast (FY)$6.57B
Ardent Health Partners, Inc. Business Overview & Revenue Model
Company Description
Ardent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The co...
How the Company Makes Money
null...
Ardent Health Partners, Inc. Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive operational and financial momentum: solid top-line growth (+7% revenue), strong adjusted EBITDA improvement (+26%, or +15% excluding a one-time investment gain), meaningful margin expansion (110 bps), demonstrable cost and labor discipline (contract labor down >40%, SW&B per AA improvements), and healthy liquidity and leverage metrics. Management acknowledged near-term volume headwinds from weather and lighter flu, exchange-related revenue pressure (~$35M estimated headwind), higher professional fees and medical malpractice premium increases, and ongoing denial-management work. On balance, the positive execution against the IMPACT program, margin gains, cash/liquidity strength, and disciplined growth initiatives outweigh the noted challenges.Positive Updates
Revenue Growth
First quarter revenue of $1.6 billion, up 7% year-over-year.
Negative Updates
Transient Volume Softness and Weather Impact
Admissions decreased 1.1% in Q1 (while adjusted admissions rose 2%); severe winter storms in Texas, Oklahoma and New Jersey and a light respiratory/flu season caused transient disruption to seasonal patterns and some fewer admissions.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
First quarter revenue of $1.6 billion, up 7% year-over-year.
Read all positive updates
Company Guidance
Management reaffirmed full‑year revenue and adjusted EBITDA guidance and reiterated adjusted admissions guidance of 1.5%–2.5% for 2026 (Q1 adjusted admissions +2.0%; total admissions -1.1%), while confirming the IMPACT program is on track to deliver $55 million of savings. Q1 highlights: revenue $1.6B (+7%), adjusted EBITDA $124M (+26%; +15% excluding a $10.9M pre‑tax investment gain), adjusted EBITDA margin 7.7% (+110 bps), pre‑NCI adjusted EBITDAR margin 11.5% (+100 bps), total surgeries +1.2% (outpatient +1.7%). Operational progress: SW&B per AA down 1.4% and SW&B as a % of revenue improved 260 bps, supply expense per AA +1.7% but supply as a % of revenue improved 50 bps, contract labor down >40% to $15M (2.2% of SW&B vs 3.8% a year ago), average hourly rate per FTE +1% YoY. Liquidity and leverage: cash $610M, total debt $1.1B, available liquidity $0.9B, Q1 cash used in ops $60M, capex $28M (expected to ramp), net leverage 1.0x and lease‑adjusted net leverage 2.6x (vs 3.0x a year ago). Management also reiterated the previously disclosed ~$35M exchange EBITDA headwind, noted exchange admissions were up ~1–2% with a ~12% shift from silver to bronze, and said professional fees are tracking to plan but should moderate to high‑single digits in the back half.Ardent Health Partners, Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
66
Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2018 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.32B | 5.97B | 5.41B | 5.13B | 4.16B |
| Gross Profit | 6.17B | 4.93B | 5.27B | 4.17B | 4.16B |
| EBITDA | 481.29M | 574.93M | 350.00M | 531.70M | 245.75M |
| Net Income | 135.81M | 210.34M | 50.29M | 188.91M | -143.02M |
Balance Sheet | |||||
| Total Assets | 5.29B | 4.96B | 5.10B | 4.86B | 2.75B |
| Cash, Cash Equivalents and Short-Term Investments | 709.60M | 556.78M | 437.58M | 456.12M | 59.66M |
| Total Debt | 2.26B | 2.28B | 2.40B | 2.39B | 1.26B |
| Total Liabilities | 3.61B | 3.43B | 4.02B | 3.81B | 2.03B |
| Stockholders Equity | 1.69B | 1.13B | 670.90M | 639.05M | 331.64M |
Cash Flow | |||||
| Free Cash Flow | 258.61M | 127.52M | 84.29M | -189.47M | -1.07M |
| Operating Cash Flow | 470.51M | 315.03M | 221.70M | -38.36M | 159.59M |
| Investing Cash Flow | -214.23M | -220.46M | -137.98M | 46.58M | -482.14M |
| Financing Cash Flow | -103.47M | 24.64M | -102.26M | -270.33M | 353.22M |
Ardent Health Partners, Inc. Technical Analysis
Positive
9.91
Price Trends
9.18
Positive
8.98
Positive
10.92
Negative
Market Momentum
0.16
Negative
66.55
Neutral
80.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Positive. The current price of 9.91 is above the 20-day moving average (MA) of 8.99, above the 50-day MA of 9.18, and below the 200-day MA of 10.92, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 66.55 is Neutral, neither overbought nor oversold. The STOCH value of 80.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARDT.
Ardent Health Partners, Inc. Risk Analysis
Ardent Health Partners, Inc. disclosed 54 risk factors in its most recent earnings report. Ardent Health Partners, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ardent Health Partners, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $2.64B | 21.34 | 11.57% | 1.80% | 17.53% | 17.13% | |
67 Neutral | $1.34B | 7.59 | 9.08% | ― | 6.72% | -39.63% | |
62 Neutral | $2.04B | 11.43 | 8.62% | 1.69% | -10.76% | -20.86% | |
53 Neutral | $1.47B | 2.30 | 953.09% | ― | 20.19% | ― | |
52 Neutral | $2.33B | 128.96 | -43.82% | ― | 6.80% | -698.20% | |
52 Neutral | $3.37B | -118.16 | 9999.00% | ― | 2.19% | -26.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ARDT
Ardent Health Partners, Inc.
9.90
-4.66
-32.01%
ACHC
Acadia Healthcare
24.46
0.24
0.99%
BKD
Brookdale Senior Living
13.56
6.90
103.60%
NHC
National Healthcare
171.42
78.61
84.71%
SEM
Select Medical
16.44
2.01
13.96%
AVAH
Aveanna Healthcare Holdings
6.94
1.44
26.18%
Ardent Health Partners, Inc. Corporate Events
Executive/Board Changes
Ardent Health Announces Leadership Change in Hospital Services
Neutral
Mar 27, 2026
On March 24, 2026, Ardent Health, Inc. announced that Ethan Chernin would no longer serve as President, Hospital Services and that he departed the company effective that day. The departure was classified as a “Qualifying Termination” u...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.